Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis

N. D. Wood; M. Aitken; S. Durston; S. Harris; G. R. McClelland; S. Sharp

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis

N. D. Wood^*, M. Aitken, S. Durston, S. Harris, G. R. McClelland, S. Sharp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC(0-∞) and C(max). Administration of 10 mg CPA following food resulted in a delayed t(max), and a significant decrease in C(max) but not AUC(0-∞).

Original language	English
Pages (from-to)	49-55
Number of pages	7
Journal	Agents and Actions Supplements
Volume	49
Publication status	Published - 12 Dec 1997

Cite this

@article{e4ba63fe1a5b409fa2546228ceca349c,

title = "Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis",

abstract = "CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC(0-∞) and C(max). Administration of 10 mg CPA following food resulted in a delayed t(max), and a significant decrease in C(max) but not AUC(0-∞).",

author = "Wood, {N. D.} and M. Aitken and S. Durston and S. Harris and McClelland, {G. R.} and S. Sharp",

year = "1997",

month = dec,

day = "12",

language = "English",

volume = "49",

pages = "49--55",

journal = "Agents and Actions Supplements",

issn = "0379-0363",

publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis

AU - Wood, N. D.

AU - Aitken, M.

AU - Durston, S.

AU - Harris, S.

AU - McClelland, G. R.

AU - Sharp, S.

PY - 1997/12/12

Y1 - 1997/12/12

N2 - CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC(0-∞) and C(max). Administration of 10 mg CPA following food resulted in a delayed t(max), and a significant decrease in C(max) but not AUC(0-∞).

AB - CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC(0-∞) and C(max). Administration of 10 mg CPA following food resulted in a delayed t(max), and a significant decrease in C(max) but not AUC(0-∞).

UR - http://www.scopus.com/inward/record.url?scp=0030728087&partnerID=8YFLogxK

M3 - Article

C2 - 9426828

AN - SCOPUS:0030728087

SN - 0379-0363

VL - 49

SP - 49

EP - 55

JO - Agents and Actions Supplements

JF - Agents and Actions Supplements

ER -

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis

Abstract

Other files and links

Fingerprint

Cite this